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Background: Retama monosperma L. (Boiss.) or Genista monosperma L. (Lam.), locally named as “R’tam”, is an
annual and spontaneous plant belonging to the Fabaceae family. In Morocco, Retama genus is located in desert
regions and across the Middle Atlas and it has been widely used in traditional medicine in many countries. In this
study, we show that Retama monosperma hexane extract presents significant anti-leukemic effects against human
Jurkat cells.
Methods: Human Jurkat cells, together with other cell lines were screened with different concentrations of Retama
monosperma hexane extract at different time intervals. Growth inhibition was determined using luminescent-based
viability assays. Cell cycle arrest and apoptosis were measured by flow cytometry analysis. Combined caspase 3 and
7 activities were measured using luminometric caspase assays and immunoblots were performed to analyze
expression of relevant pro- and anti-apoptotic proteins. GC-MS were used to determine the chemical constituents
of the active extract.
Results: Retama monosperma hexane extract (Rm-HE) showed significant cytotoxicity against Jurkat cells, whereas it
proved to be essentially ineffective against both normal mouse fibroblasts (NIH3T3) and normal lymphocytes (TK-6).
Cytometric analysis indicated that Rm-HE promoted cell cycle arrest and apoptosis induction accompanied by DNA
damage induction indicated by an increase in p-H2A.X levels. Rm-HE induced apoptosis was partially
JNK-dependent and characterized by an increase in Fas-L levels together with activation of caspases 8, 3, 7 and 9,
whereas neither the pro-apoptotic nor anti-apoptotic mitochondrial membrane proteins analyzed were significantly
altered. Chemical identification analysis indicated that α-linolenic acid, campesterol, stigmasterol and sitosterol were
the major bioactive components within the extract.
Conclusions: Our data suggest that bioactive compounds present in Rm-HE show significant anti leukemic activity
inducing cell cycle arrest and cell death that operates, at least partially, through the extrinsic apoptosis pathway.
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Medicinal plants used in traditional or folk medicine and
their active compounds, used in conventional medicine,
constitute the basis for the treatment of many diseases
including cancer, one of the major causes of mortality
throughout the world. Statistics have estimated that cancer
will cause 83.2 million deaths between 2005 and 2015 [1].
Clinical applications have, for many decades, demon-
strated their therapeutic effects. In fact, 40% of all available
anticancer drugs are natural products or natural product-
derived mimics, such as paclitaxel (from Taxus brevifolia),
camptothecin (from Camptotheca acuminata), podophyl-
lotoxin (from Podophyllum emody) and vinblastine (from
Catharanthus roseus), which are widely-used anticancer
agents [2].
Retama monosperma L. (Boiss.) or Genista monosperma
L. (Lam.), locally named as “R’tam”, is an annual and
spontaneous plant belonging to the Fabaceae family. The
genus Retama includes four species with a geographic
distribution in the Mediterranean area, North Africa,
and the Canary Islands [3]. In Morocco, Retama genus
is largely located in desert regions and the Middle Atlas
[4]. This plant is used in traditional medicine in many
countries, as purgative, vermifuge, antihelmintic, and
abortive [5]. Moreover, several studies have investigated
Retama genus for various pharmacological effects, in-
cluding hypoglycemic and diuretic [4,6], cytotoxic [7,8],
antioxidant, antiviral [9], antihypertensive [10], anti-
inflammatory [11] and antitumor activities [12].
T-cell malignancies are highly aggressive neoplastic
disorders that are generally resistant to conventional
chemotherapy with a high rate of relapse and currently
no efficient targeted therapies available for these dis-
eases [13]. In order to extend the treatment options and
ultimately improve survival for patients with leukemia,
it is imperative to increase the therapeutic arsenal of
targeted therapies involving apoptotic cell death, that
has been proposed as an efficient mechanism by which
malignant tumor cells can be removed upon treatment
with chemotherapeutic drugs without accompanying a
local damaging inflammatory response [14].
In chemotherapeutic drug-induced apoptosis of tumor
cells, three different death signaling pathways can lead to
apoptosis: the extrinsic death receptor-dependent pathway
[15], the intrinsic mitochondria-based pathway [16], and
the intrinsic endoplasmic reticulum (ER) stress-mediated
pathway [17].
In this study, we show that Retama monosperma hexane
extract presents selectively an anti-leukemic effect, as
indicated by its dramatic effects on Jurkat, but not other
human cancer cells of various origins. We describe
herein the major cellular effects of Rm-HE leading to
cell cycle arrest and extrinsic pathway-dependent apop-
tosis. Finally, we suggest potential bioactive compoundsresponsible for these effects upon the determination of
the chemical components of the extract by GC/MS.
Methods
Plant material
Leaves of Retama monosperma L. (Boiss.) were collected
in March 2009 from Sidi Boughaba reserve in Mehdia-
Rabat (Morocco). The plant was identified at the Scientific
Institute of Rabat by Prof. M. Fennane, and the specimen
was deposited in the Scientific Institute herbarium under
the voucher specimen reference N° RAB78140.
Preparation of hexanic extract
The powder of the dried plant was extracted successively
using a Soxhlet apparatus with n-hexane to obtain hexanic
extract (Rm-HE). The resulting extract was then evapo-
rated by a Rotavapor to obtain the dried extract and was
kept at -20°C until use.
Cell culture
Jurkat, TK6 and Jeko-1 cells were maintained in RPMI-
1640 with L-Glutamine and HEPES (Biological Indus-
tries Ltd., Kibbutz Beit Haemek, Israel). LN229, T98G,
U87MG, SW620, SW480, U2OS, PC-3 and NIH3T3
cells were maintained in DMEM High Glucose (4.5 g/l)
with L-glutamine (Invitrogen, Carlsbad, CA). All cells were
grown in a humidified incubator at 37°C with 5% CO2.
RPMI and DMEM were supplemented with 10% heat inac-
tivated foetal bovine serum and 100 units/ml penicillin/
streptomycin (Biological Industries Ltd., Kibbutz Beit
Haemek, Israel). All cell lines were subconfluently grown
and passaged, routinely tested for mycoplasma contamin-
ation and subjected to frequent morphological tests and
growth curve analysis as quality-control assessments. All
cell lines were treated at a prophylactic concentration of
5 μg/ml with Plasmocin™ (Invivo Gen, San Diego, CA).
Drugs and inhibitors
Doxorubicin (Developmental Therapeutics Program, Div-
ision of Cancer Treatment and Diagnosis, National Cancer
Institute, Bethesda, MA), Q-v-Ophand and SP600125
(Calbiochem, Darmstadt, Germany) were added directly
to the media at the indicated concentration and cells
were harvested or analyzed at the time points indicated
in the figure legends.
Cell viability assays
The number of viable cells in culture was determined
based on quantification of ATP, which signals the presence
of metabolically-active cells, using the Cell Titer-Glo lumi-
niscent assay kit (Promega, Madison, WI, USA), which is
quicker than other commonly-used methods to measure
the number of viable cells (such as MTT, alamar Blue® or
Calcein-AM) that require prolonged incubation steps to
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molecules into a detectable signal. Following the manufac-
turer’s instructions, the cells were plated in 96-well plates,
treated 24 h later with extracts dissolved in DMSO for the
indicated times and concentrations followed by addition
of Cell Titer-Glo reagent. Luminiscence was detected
using a multi-well Synergy Mx scanning spectrophotom-
eter (Biotek, Winooski, VT).
Cell cycle analysis
Cell cycle analysis was performed using propidium iod-
ide staining. Briefly, cells were washed in phosphate-
buffered saline (PBS) and fixed in 70% ethanol. Fixed
cells were then washed twice in PBS and stained in pro-
pidium iodide (50 μg/ml) in the presence of 50 μg/ml
RNase A (Sigma-Aldrich, St Louis, MO, USA), then
analyzed by flow cytometry using a FACScan (Coulter
Epics XL-MSL; Beckman Coulter, Fullerton, CA, USA)
and winMDI software.
Annexin V-FITC/propidium iodide flow cytometric analysis
Analysis of phosphatidylserine externalization in apoptotic
cells was determined by an Apo Target Annexin-V-FITC
Apoptosis kit (Invitrogen, Carlsbad, CA), according to the
manufacturer’s instructions. 2 × 10cells were seeded in 6-
well plates and treated with 50 μg/ml of Rm-HE for 48 h.
They were then collected and suspended in 100 μl of
Annexin V-binding buffer. 5 μL of Annexin-V-FITC and
10 μL of propidium iodide were added and incubated
15 min at room temperature in the dark. Flow cytometry
analysis was carried out using a FACScan (Coulter Epics
XL-MSL; Beckman Coulter, Fullerton, CA, USA) and
winMDI software.
Caspase activity analysis
Enzymatic activity of caspases was determined by meas-
urement of caspases-3 and 7 activity by means of the
luminometric Caspase-Glo 3/7assay (Promega, Madison,
WI, USA) according to the manufacturer’s protocol using
a Synergy HT multi-detection microplate reader (Bio-Tek,
Winooski, VT, USA).
Gel electrophoresis and immunoblotting
Cells were harvested in a buffer containing 50 mMTris-
HCl pH 7.4, 150 mMNaCl, 1 mM EDTA and 1% (v/v)
Triton X-100 plus protease and phosphatase inhibitors.
Protein content was measured by the Bradford procedure.
Cell lysates were electrophoresed in SDS-polyacrylamide
gels. After electrophoresis the proteins were transferred to
Immobilon-P strips (Millipore, Billerica, MA) for 2 h at
60 V. The sheets were pre-incubated in TBS (20 mMTris-
HCl pH 7.5, 150 mMNaCl), 0.05% Tween 20 and 5%
defatted milk powder for 1 h at room temperature and
then incubated for 1 h at room temperature in TBS,0.05% Tween 20, 1% BSA and 0.5% defatted milk powder
containing the appropriate antibodies: pH2A.X (#9718,
1:1000), Cleaved Caspase-3 (#9464, 1:1000), Cleaved
Caspase-7 (#8438, 1:1000), Cleaved Caspase-9 (#7237,
1:1000), Caspase-8 (#9746, 1:1000), Bcl-2 (#2870, 1:1000),
Bcl-xl (#2764, 1:1000) and Mcl-1 (#5453, 1:1000) from
Cell Signaling (Beverly, MA); Bax (BD610391, 1:1000) and
Bad (BD610982, 1:1000) from BD Transduction Labora-
tories™ (California, USA); Bim (22–40, Millipore, Billerica,
MA, 1:1000); Fas-L (sc-6237, 1:1000), JNK (sc-137018,
1:1000) and pJNK (sc-135642, 1:1000) from Santa Cruz
(Santa Cruz, CA) and β-tubulin (T0198, Sigma-Aldrich,
St. Louis, MO, 1:4000). After washing in TBS, 0.05%
Tween 20, the sheets were incubated with a peroxidase-
coupled secondary antibody (Dako, Glostrup, Denmark, 1/
2000 dilution,) for 1 h at room temperature. After incuba-
tion, the sheets were washed twice in TBS, 0.05% Tween
20 and once in TBS. The peroxidase reaction was visual-
ized by the enhanced chemiluminiscence detection system
(Millipore, Billerica, MA).
Derivatization for GC/MS analysis
For this purpose 100 μl of the extract was dried with
N2 gas, then 100 μl of derivatization agent (N, O-bis
(trimethylsilyl) trifluoroacetamide with 1% of trimethyl-
chlorosilane) was added, mixed and heated 10 minutes at
60°C.
Gas chromatography/mass spectrometry (GC/MS) analysis
The GC-MS analyses of Retama monosperma hexanic
extract (Rm-HE) were carried out at the Instrumental
Technical Services of the “Estación Experimental del
Zaidín” (CSIC, Granada, Spain). Briefly, 1 μl of the de-
rivative solution was injected in a Varian 450GC coupled
to 240 Ion Trap Mass Spectrometer as detector. The in-
jection conditions were: splitless mode with 1 minute
duration pulse, the injector temperature was 250°C; the
He column flow was 1 ml/minute in a capillary column
(Varian Factor Four VF-5 ms 30 m×0.25 mm×0.25 μm).
For Mass spectrometry conditions, the EI ionization was
70 eV, the transfer line was at 280°C and the Trap at
240°C, mass range acquisition was from m/z 50 to m/z
500 and cared in Full Scan mode. Qualitative analysis of
compounds was based on the comparison of their spec-
tral mass and their relative Retention time with those of
NIST08 mass spectra database and Kovats RI on the
chromatograms recorded in Full Scan or in SIM mode
using the characteristics ions. Quantitative analysis was
realized by integration of peaks and calculated as percent
of total identified area on the TIC chromatograms.
Statistical analysis
Data are presented as means ± SD of at least three differ-
ent assays performed in triplicate. IC50 value and the
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were assessed using GraphPad Prism (GraphPad Software
Inc. La Jolla, CA). Statistically significant differences are
indicated by ***P, 0.001, **P, 0.01 and *P, 0.05, respectively.
Results
Analysis of the cytotoxic activity of Rm-HE against human
cancer cell lines
To investigate the potential effect of Rm-HE extract
against cancer cells, various human cancer cell lines of
different origin were screened to assess the cytotoxic
activity of Rm-HE. Non-tumoral cell lines NIH3T3 and
TK6 were also tested as control. Interestingly, Rm-HEFigure 1 Analysis of the cytotoxic activity of Rm-HE against human c
Extract (Rm-HE) in a panel of cancer and non-transformed cell lines. LN229
were incubated for 48 h with 50 μg/ml of (Rm-HE); Results represent the m
percentage of viable cells relative to vehicle-treated (control) cells. (B) Dose
and IC50 determination on Jurkat cells. Cells were treated with Rm-HE for 4
(μg/ml) was determined graphically from the viability curves, NIH3T3 and T
triplicate determinations.extract was dramatically effective against Jurkat cells
whereas it induced only modest or negligible effects in
the other tested cell lines (Figure 1A). We next per-
formed a dose-response (0-50 μg/ml) viability assay in
Jurkat cells in order to calculate the IC50 for this cell
line, using NIH3T3 and TK6 cells as controls. The ob-
tained cell growth curves in Figure 1B prove that Rm-HE
exerts a specific dose-dependent inhibitory effect on cell
proliferation in Jurkat cells (IC50 = 34.44 ± 3.88 μg/ml). In
agreement with our previous results, the extract exhibited
no effects on NIH3T3 and TK6 (non-transformed cells
lines) and a dose of 40 μg/ml was chosen for further
mechanistic studies in Jurkat cells.ancer cell lines. (A) Cytotoxic activity of Retama monosperma Hexanic
, T98, U87, Jurkat, Jeko-1, SW620, SW480, U2OS, PC-3 and NIH3T3 cells
ean ± SD of at least 3 independent experiments indicating the
-response analysis of Retama monosperma Hexanic Extract (Rm-HE)
8 h at different concentrations ranging from 1 to 50 μg/ml; IC50 value
K6 cells were used as control. Data are expressed as means ± SD of
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In order to investigate how Rm-HE affects cell cycle dis-
tribution, Jurkat cells were treated with a concentration
of 40 μg/ml for 24 and 48 h. As shown in Figures 2A
and B, Rm-HE effectively reduced the proportion of
S-phase cells while strongly increasing the proportion of
sub-G1 cells (33.05% at 24 h and 43.48% at 48 h). To elu-
cidate the possible mechanism of Rm-HE induced sub-G1
population, we analyzed the presence of DNA damage byFigure 2 Analysis of cell cycle effects and cell apoptosis of Rm-HE in
monosperma Hexanic Extract (Rm-HE) by flow cytometry. Jurkat cells (4 × 10
24 h and 48 h. Cells were harvested and their DNA content analysed by flo
distribution is shown for each experimental condition. (B) The graph summ
cells, respectively. (C) Effect of Rm-HE on pH2A.X levels. Cells (4 × 10cells /m
levels in cellular extracts were detected by immunoblot with specific antib
Jurkat cell apoptosis analyzed by flow cytometry. Cells were treated with 4
staining and y-axis indicates Propidium iodide staining; Lower left (LL) quad
left (UL) quadrant: necrotic cells, upper right (UR) quadrant: late apoptotic cmonitoring p-H2A.X levels. As shown in Figure 2C, in-
creased levels of p-H2A.X were detected in Jurkat cells
after only 4 h, suggesting that Rm-HE treatment induced
DNA damage. Double Annexin V/Propidium Iodide
staining was next performed in order to analyze and
quantify cellular death. Upon exposure to Rm-HE, a
time-dependent increase in the number of Annexin V-
positive cells (37%) at 24 h was observed (Figure 2D).
Taken together, these data indicate that Rm-HE inducesJurkat cells. (A) Cell cycle analysis of Jurkat cells treated with Retama
cells/ml) were incubated with 40 μg/ml of Rm-HE as indicated for
w cytometry as described in Materials and Methods. The cell cycle
arizes the percentage of each phase in control, 24 h and 48 h-treated
l) were treated with 40 μg/ml Rm-HE for 0, 2, 4, 8 and 16 h. p-H2A.X
odies. Tubulin was used as an internal control. (D) Effect of Rm-HE in
0 μg/ml of Rm-HE for 12 h and 24 h. The x-axis shows Annexin V-FITC
rant: viable cells; lower right (LR) quadrant: early apoptotic cells; upper
ells.
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tosis in Jurkat cells.
Effects of Rm-HE on apoptosis induction in Jurkat cells
Activation of aspartate-specific cysteine proteases also
known as caspases is a crucial biochemical event dur-
ing apoptosis [18,19]. Different caspases are activated
during the initiation and execution phases of apop-
tosis. To investigate if Rm-HE-induced apoptosis is
caspase dependent, we performed caspase 3/7 activity
assays upon treatment of Jurkat cells with 40 μg/ml
Rm-HE for 24 and 48 h. Doxorubicin (1 μM), a con-
ventional drug inducing caspase-dependent apoptosis
was used as positive control. Figure 3A showed that
both treatments similarly increased caspase activity up
to 3-fold upon 48 h. Accordingly, the presence of a
specific caspase inhibitor (QVD-OPh) significantly re-
duced the cytotoxic effects of both Doxorubicin and






















Figure 3 Effects of Rm-HE on apoptosis induction and activation of c
Extract on caspase activity induction on Jurkat cells. Jurkat cells were treate
24 h and 48 h and caspase activity was measured as indicated in Materials
caspase activity relative to untreated cells from three independent determi
Hexanic Extract on viability in the presence of a caspase inhibitor Jurkat ce
(40 μg/ml) was added for 24 h. Doxorubicin was used as positive control. C
and data is means ± S.E.M. from three independent determinations perform
the expression and cleavage of caspases 8, 7, 3 and 9 in Jurkat cells. 4 × 10
and cleaved caspase levels in cellular extracts were detected by immunoblDifferent caspases are activated by proteolytic cleavage
at the initiation and execution phases of apoptosis [20].
To determine the effect of Rm-HE on the activation of
caspases, we monitored cleavage of caspases 8, 7, 3 and
9 in Jurkat cells following Rm-HE treatment at different
time-points. Results of western blot analysis shown in
Figure 3C indicate that Rm-HE treatment caused a strong
activation of caspase 8 (detected at 4 h) together with the
activation of caspases 7, 3 and 9 in a time-dependent
manner. This observation confirms that Rm-HE-induced
apoptosis is caspase-dependent and suggests that it oper-
ates via the extrinsic pathway.
Characterizion of the effects of Rm-HE on apoptotic
signaling mediators
Two major pathways are known to mediate cellular apop-
tosis, death receptor-dependent (extrinsic) and mitochon-
drial (intrinsic) pathways. Since our results suggest that





























aspases in Jurkat cells. (A) Effect of Retama monosperma Hexanic
d with Rm-HE (40 μg/ml) or 1 μM Doxorubicin (positive control) for
and Methods. Results indicate the average fold increase ± S.E.M in
nations performed in duplicate. (B) Effect of Retama monosperma
lls were pre-incubated for 1 h with 5 μM Q-VD-OPh and Rm-HE
ell viability is represented as a percentage relative to untreated cells,
ed in duplicate. (C) Effect of Retama monosperma Hexanic Extract on
cells were treated with Rm-HE (40 μg/ml) for 0, 2, 4, 8 and 16 h. Total
ot with specific antibodies. Tubulin was used as an internal control.
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the expression of specific proteins involved in either of
these pathways. To this end, we analyzed the expression
levels of both pro- and anti-apoptotic members of the Bcl-
2 family. Western blot analysis indicated that the expres-
sion levels of the anti-apoptotic proteins Bcl-xL, Mcl-1,
and Bcl-2 [20,21], were not significantly altered upon Rm-Figure 4 Characterizion of the effects of Rm-HE on apoptotic signalin
apoptosis-related proteins in Jurkat cells. Expression of the anti-apoptotic p
treated as indicated by immunoblot with specific antibodies. Tubulin was u
Bim, Bax and Bad was analyzed in extracts of Jurkat cells treated as indicate
internal control. (C) Fas Ligand induction was analyzed in extracts of Jurkat
Tubulin was used as an internal control. (D) Statistical analysis for Fas-L exp
increase ± S.E.M in Fas-L expression relative to untreated cells from three in
cells treated for 16 h with Rm-HE are statistically significant (Student’s t-tes
of a JNK inhibitor. Jurkat cells were pre-incubated for 1 h with 10μMSP6001
indicated. Cell viability is represented as a percentage relative to untreated
performed in duplicate. (F) Effect of Rm-HE on the JNK phosphorylation in
extracts of Jurkat cells treated as indicated by immunoblot with specific anHE treatment (Figure 4A). Regarding the pro-apoptotic
members of the family, neither Bax nor Bad showed a sig-
nificant increase upon Rm-HE, whereas Bim levels were
modestly increased (Figure 4B). Since caspase-8 is gener-
ally activated following assembly of death-inducing signal-
ing complex (DISC) during receptor-mediated apoptosis,
we next investigated the expression of Fas ligand, a majorg mediators. (A) Effect of Rm-HE on the expression and cleavage of
roteins Bcl-XL, Mcl- 1 and Bcl-2 was analyzed in extracts of Jurkat cells
sed as an internal control. (B) Expression of pro-apoptotic proteins
d by immunoblot with specific antibodies. Tubulin was used as an
cells treated as indicated by immunoblot with specific antibodies.
ression blots in Rm-HE treated cells. Results indicate the average fold
dependent experiments. The difference between untreated cells and
t: **P < 0.01). (E) Effect of Rm-HE on Jurkat cell viability in the presence
25 and then 40 μg/ml of Rm-HE were added for 24 h and 48 h, as
cells. Data is means ± S.E.M. from three independent determinations
Jurkat cells. Expression of JNK and phospho-JNK were analyzed in
tibodies. Tubulin was used as an internal control.
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hanced Fas-L expression upon exposure to Rm-HE; the
statistical analysis of Fas-L blots in Figure 4D showed an
expression increase up to 3-fold upon 16 h of treatment.
Accordingly, the inhibition of JNK, a key regulator of
Fas-L expression, partially reduced the cytotoxic effects
of Rm-HE on Jurkat cells (Figure 4E), in agreement with
the observed increase in JNK phosphorylation upon time
(Figure 4F). Altogether, these observations suggest that
apoptosis induced by Rm-HE is activated, at least partially,
via the caspase-8-dependent extrinsic pathway.
Characterization of chemical compounds in Retama
monosperma hexanic extract
In order to identify putative bioactive compounds re-
sponsible for these effects, Rm-HE was subjected to
Gc-MS analysis (Figure 5). At least 60 compounds
were present in Rm-HE, of which 43 were identified using
mass spectrometry. Retention time, Cas Numbers and %Figure 5 Characterization of chemical compounds in Retama monosp
Hexanic Extract (Rm-HE) obtained by CG. Compounds were identified by c
fragmentation patterns were compared with literature data. Rm-HE constitu
bioactive compounds ofRetama monosperma Hexanic Extract.of identified area are summarized in Table 1. The mass
spectra of these compounds were matched with computer
searches in the references libraries of NIST08 and Wiley7,
and fragmentation patterns were compared with litera-
ture and commercially-available products data. The major
bioactive compounds identified were α-Linoleic acid
(13.97%), Stigmasterol (10.34%), β-Sitosteryl (7.92%) and
Campesterol (11.09%). Figure 5B shows their chemical
structures.
Discussion
Many current research efforts in the field of cancer thera-
peutics are focused on the development of highly specific
agents able to selectively induce apoptosis in cancer, but
not normal, cells. In the last two decades there has been a
surge of anti-cancer drugs introduced, of which almost
half of them are derived from natural sources [22,23]. In
Morocco, traditional medicine is supported by one of
the world's oldest pharmacopoeia, with an environmentalerma hexanic extract. A) Chromatogram of Retama monosperma
omputer searches in the reference libraries of NIST and Wiley7, and
ent are shown in Table1. (B) Chemical structures of the major
Table 1 Compounds present in hexanic extract of Retama monospermaidentified by CG/MS
RT Identified compounds cas numbers % Area
15,886 Propanoic Acid,2-[(trimethylsilyl)oxy]-, trimethylsilyl ester 17596-96-2 0,09
16,386 HexanoicAcid, trimethylsilylester 14246-15-2 0,04
16,46 Acetic acid, (trimethylsiloxy)-, trimethylsilyl ester 33581-77-0 0,027
21,694 Silanol,1,1,1-trimethyl-, 1-benzoate 2078-12-8 0,063
22,167 OctanoicAcid, trimethylsilylester 55494-06-9 0,063
24,805 NonanoicAcidtrimethylsilylester 82326-11-2 0,289
26,452 Dicyclohexylamine 101-83-7 0,139
27,305 DecanoicAcid, trimethylsilylester 55494-15-0 0,072
28,004 malatate 65143-63-7 0,036
29,279 TrimethylsilylVanillin 6689-43-6 0,103
29,368 (S)-dihydroactinidiolide 17092-92-1 0,257
31,347 P-Hydroxybenzoic Acid TMS ether TMS ester 2078-13-9 0,099
31,927 DodecanoicAcid, trimethylsilylester 55520-95-1 0,736
35,036 Nonanedioic Acid bis(trimethylsilyl) ester 17906-08-0 0,162
35,441 SPARTEINE 90-39-1 0,952
36,12 TetradecanoicAcidtrimethylsilylester 18603-17-3 0,686
37,734 methylpalmitate 112-39-0 0,374
38,077 PentadecanoicAcidtrimethylsilylester 74367-22-9 0,519
39,982 PalmiticAcidtrimethylsilylester 55520-89-3 2,406
40,124 Cytisine/baptitoxine/sophorine/Caulophylline 486-86-2 0,171
41,748 HeptadecanoicAcid, trimethylsilylester 55517-58-3 0,259
42,069 Aphylline 577-37-7 2,83
42,221 Phytol 352332 1,973
42,996 LinoleicAcidtrimethylsilyl 56259-07-5 9,988
43,156 α Linoleic Acid trimethylsilyl ester 97844-13-8 13,976
43,52 OctadecanoicAcid, trimethylsilylester 18748-91-9 1,35
43,723 Lupanine 550-90-3 0,212
45,127 NonadecanoicAcidtrimethylsilylester 74367-35-4 0,55
45,59 oleamide/SLEEPAMIDE 301-02-0 1,291
46,746 EicosanoicAcid, trimethylsilylester 55530-70-6 2,853
47,814 Monolupine /anagyrine 486-89-5 2,275
48,903 Hexadecanoic Acid 2,3-bis[(trimethylsilyl)oxy]propyl ester 1188-74-5 2,569
49,742 DocosanoicAcidtrimethylsilylester 74367-36-5 2,804
50,022 (-)-PTEROCARPIN 524-97-0 0,329
50,197 OctadecanedioicAcid di(trimethylsilyl) ester 22396-20-9 0,438
51,265 1-TETRACOSANOL 506-51-4 3,65
51,684 Stearic Acid 2,3-bis(trimethylsilyloxy)propyl ester 1188-75-6 2,041
53,094 Brucine 357-57-3 0,654
53,702 PentacosanoicAcid 506-38-7 0,487
53,769 HexacosanoicAcid 506-46-7 2,781
57,238 Stigmasteroltrimethylsilylether 14030-29-6 10,34
57,609 β-Sitosteryltrimethylsilylether 2625-46-9 7,92
58,525 CAMPESTEROL 474-62-4 11,086
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[24]. Currently, plants of the Retama genus have attracted
an increasing interest due to their wide range of pharma-
cological effects including hypoglycemic and diuretic [4,6],
cytotoxic [7,8], antioxidant, antiviral [9], antihypertensive
[10], anti-inflammatory [11] and antitumor activities [12].
In correlation with our previous observations indicating
an anti-leukemic effect of Rm-HE [25], we confirm and
extend herein the anti-leukemic and apoptotic-inducing
effects of Rm-HE and indicate its cellular mechanism of
action on Jurkat cells. For this purpose, a cytotoxic screen-
ing with Rm-HE was performed on a panel of established
human cancer cell lines including Glioblastoma Multi-
forme, Acute T cell Leukemia, Mantle Cell Lymphoma,
Colon cancer, Prostate Cancer and Osteosarcoma cells, to-
gether with non-tumoral control cell lines. In this context,
Rm-HE exhibited a dramatic effect on Jurkat cells, which
are usually used as a model of acute T cell leukemia, but
was essentially ineffective against the other tested cell lines
including a B-cell lymphoma cell line (Jeko-1). Interest-
ingly, Acute T cell leukemia is a hematological malignancy
characterized by a deregulated expression of apoptosis-
related molecules [26].
Interestingly, flow cytometry analysis confirmed that
exposure to Rm-HE strongly promoted cell death as
indicated by the dramatic time-dependent increase in
the proportion of sub-G1 cells. In parallel with cellular
death, we observed that the number of cells in S-phase
was also reduced, indicating a block in cell cycle pro-
gression. DNA damage is one of the major mechanisms
behind anticancer drug-induced cell cycle arrest and
apoptosis [27,28]. Under normal conditions, genomic
integrity in DNA damaged-cells is usually restored
through DNA repair. If DNA repair cannot be achieved
properly or cells are overwhelmed by sustained dam-
age, apoptosis ensues in order to remove genetically
aberrant cells [29,30]. In agreement with the induction
of apoptosis, we observed that Rm-HE treatment elic-
ited DNA damage at 4 h as indicated by the increase in
H2A.X phosphorylation, a well-established readout for
the presence of double strand breaks [31].
In order to better understand the mechanisms of cellular
death in response to Rm-HE, we performed flow cytome-
try analysis upon Annexin-V/ propidium iodide staining
to detect and quantify the amount of cells undergoing
apoptosis [32]. In this setting, the number of Jurkat cells
entering early apoptosis clearly increased in a time-
dependent manner, demonstrating that Rm-HE treat-
ment induces Jurkat cell death through the promotion
of apoptosis. Since a fundamental requirement for
apoptosis to take place is the activation of caspases
[18,19], we determined if the enzymatic activity of cas-
pases 3 and 7 was increased in Jurkat cells upon Rm-HE
treatment. As expected, Rm-HE clearly induced caspaseactivation to a similar extent as the conventional che-
motherapeutic agent Doxorubycin, and in correlation
with this, the inhibition of caspases resulted in a partial
protection against Rm-HE-mediated cytotoxicity.
Two fundamental pathways are responsible for the in-
duction of apoptosis: the mitochondrial or intrinsic path-
way and the death receptor or extrinsic pathway [32].
Western blot analysis confirmed that both executioner
caspases 3 and 7 were cleaved and thus activated by Rm-
HE treatment, in parallel with the results obtained in cas-
pase activity assays. Remarkably, Rm-HE treatment rapidly
led to procaspase 8 cleavage, which is indicative of activa-
tion of the extrinsic apoptotic pathway, an event that was
followed by subsequent activation of caspase 9.
In order to understand the involvement of both intrinsic
and extrinsic apoptotic pathways in this process, we fur-
ther investigated molecular events related to both apop-
totic pathways in Rm-HE-treated Jurkat cells. To this
end, we investigated the activation of both anti- and
pro-apoptotic members of the Bcl-2 family. The absence
of significant alterations in members of this family in
Rm-HE-treated cells pointed to the induction of apop-
tosis predominantly via the receptor-activated extrinsic
pathway. Activation of the extrinsic apoptotic pathway is
regulated downstream of the activation of death receptors,
and involves ligand-induced formation of death-inducing
signaling complex (DISC) that recruits and activates
pro-caspase 8. Since a major activator of death recep-
tors in human leukemic cells is Fas-ligand (Fas-L) [33],
we next investigated whether Rm-HE treatment could
induce Fas-L upregulation. Interestingly, we observed a
time-dependent increase in Fas-L in Rm-HE-treated
Jurkat cells. A key upstream molecular pathway leading
to Fas-L expression is the stress-activated JNK pathway
[34,35], which has been shown to lead through Fas-L to
caspase 8 and caspase 3 activation [36]. Accordingly,
JNK inhibition significantly reduced the cytotoxic effects
of Rm-HE in Jurkat cells, suggesting that a JNK/Fas-L/
caspase 8/caspase 3 pathway is activated following Rm-
HE treatment to promote extrinsic pathway-dependent
apoptosis in Jurkat cells. We cannot rule out the contri-
bution of the caspase 8-independent, intrinsic apoptotic
pathway to Rm-HE-induced apoptosis, as indicated by
the detection of caspase 9 cleavage. However, the robust
effects on caspase 8, together with our observations on
the involvement of JNK and Fas-L suggest that the extrin-
sic pathway is the predominant apoptotic pathway in our
experimental conditions.
We finally performed GC-MS analysis in order to iden-
tify putative bioactive compounds responsible for these
cellular effects. Four major bioactives compounds were
identified: α-Linoleic acid, Campesterol, β- sitosterol and
stigmasterol. When combined together, the last three have
been shown to exert cytotoxic activity against cancer cells
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cell growth that was not dose-responsive (around 40–50%
inhibition between 1.6 and 50 μg/ml) in HS578T breast
cancer cells [37]. Additionally, ß -sitosterol and phytol,
which is also present in Rm-HE, exhibited a clear cytotox-
icity against various cancer cell lines including nasopha-
ryngeal epidermoid carcinoma, breast cancer, cervical
carcinoma, colon carcinoma and lung adenocarcinoma
cells [38]. These observations support the notion that the
combination of several bioactive compounds in Rm-HE
exerts its anticancer activity, and pave the way for further
research efforts aimed at elucidating if any of the identified
compounds could be mainly responsible for these effects.
Conclusions
Our results suggest that bioactive components of Rm-HE
act either alone or in combination to promote cellular
apoptosis, predominantly acting via the extrinsic apoptosis
pathway, with a strong selectivity against human T cell
leukemia. The mechanism whereby this extract induces
apoptosis is likely to involve a JNK/Fas-L/caspase 8/
caspase 3 pathway in the presence of cell cycle arrest
and DNA damage induction. Further studies are required
to i) understand the molecular basis of its antileukemic se-
lectivity, ii) determine which of the identified bioactive
compounds are responsible for these effects and iii) per-
form preclinical developmental research aimed at ensuring
its safety and efficacy as therapeutic agents.
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